Substance AbusePIPNCT01090245
Using Incentives to Improve Parolee Participation and Attendance in Community Treatment
A study testing Contingency management: voucher/monetary incentives for treatment attendance and Information in people with Substance Abuse and HIV Infections, run by University of California, Los Angeles.
Trial summary
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in… Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Substance Abuse, HIV Infections
- What is being tested?
- Contingency management: voucher/monetary incentives for treatment attendance and Information
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 202 participants
- Where
- No sites listed yet
- Study dates
- Apr 2010to Aug 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- At least 18 years of age
- English speaking
- Within one month of parole
- Able to provide informed consent to participate in the study
- Received a referral to the Walden House Los Angeles Transitional Treatment Center
Who cannot join
- Potential subjects will be excluded from participating if they have serious cognitive problems that preclude their ability to provide informed consent or understanding of the questionnaire items, if they are a sexually violent predator or a child molester or if they have severe mental health problems.
About this study
Official title: Using Incentives to Improve Parolee Participation and Attendance in Community Tx
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment program to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.
Read more
Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.
Read the detailed description
A considerable body of research indicates that prison-based treatment followed by continuing treatment in the community is effective in reducing drug abuse and crime among drug-abusing offenders. However, the impact of providing treatment is less than optimal because offenders often fail to follow through on treatment referrals, leave treatment early, or have poor engagement in treatment activities. In particular, participation in prison-based treatment alone is seldom effective in reducing drug use or recidivism unless it is followed by participation in community treatment. For correctional systems that provide a continuum of care model from prison to community, low rates of admission and retention result in poor outcomes and poor resource utilization. One way to address this problem is to provide incentives to parolees for community treatment participation. Although research supports the effectiveness of behavioral reinforcement, mainly in the form of contingency management (CM), for general substance abuse populations, CM has not yet been tested or adapted for use in community-based programs for offender populations, particularly to encourage treatment attendance.
In addition, recent research has documented elevated rates of HIV infection among incarcerated populations compared to the general population, with prevalence of HIV among inmates in US prisons being estimated to be 6 to 10 times higher than in the general population. Upon release from prison, parolees often immediately resume high-risk behaviors that they engaged in prior to incarceration. Because of the high level of exposure to HIV infection that accompanies drug use, particularly by injection, drug treatment programs for high-risk offenders can serve as a valuable setting for preventing the spread of HIV, both through HIV prevention/education activities and through access to HIV testing and counseling.
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.
- Conditions
- Substance Abuse, HIV Infections
- Being tested
- Contingency management: voucher/monetary incentives for treatment attendance, Information
- Keywords
- contingency management, substance abuse treatment, criminal justice populations, substance abuse treatment retention, HIV prevention in criminal justice settings, voucher based reinforcement therapy, Parole treatment admission for substance abusing parolees, Parole treatment retention for substance abusing parolees, HIV testing and counseling for substance abusing parolees
- Medical subject headings
- Substance-Related Disorders, HIV Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Contingency management: voucher/monetary incentives for treatment attendanceBehavioural
Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
InformationBehavioural
Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
| Study group | Role | What they receive |
|---|---|---|
| Attendance Information Group | Active comparator | Participants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program. Receives: Behavioral: Information |
| Attendance Incentive Group | Experimental | Participants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program. Receives: Behavioral: Contingency management: voucher/monetary incentives for treatment attendance |
What is being measured
The primary outcome is the main question the study is designed to answer.
Community treatment admission
Measured: Within 7 days of release to parole
Community treatment retention
Measured: 6 months
Participation in HIV testing and counseling
Measured: 2 months
Secondary outcomes (3)
Substance abuse
Measured: 18 months after release from prison
Arrest and reincarceration
Measured: 18 months after release from prison
psychosocial: employment, education, family relationships, psychological functioning, and HIV risk
employment, education, family relationships, psychological functioning, and HIV risk
Measured: 18 months after release from prison
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Mar 2010 (estimated)
- Study startApr 2010
- Primary completionJan 2014
- Study completionAug 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Substance AbuseStudies of the same condition, open and under way.
- More trials run by University of California, Los AngelesThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 202 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Los Angeles
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michael Prendergast, University of California, Los Angeles
- Investigators
- Michael L Prendergast, Ph.D., Principal investigator, University of California, Los AngelesElizabeth A Hall, Ph.D., Study director, University of California, Los Angeles
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01090245
- Sponsor's protocol ID
- 1R01DA025627-01A1
- Acronym
- PIP
- Status last verified
- May 2017
- First submitted
- 16 Mar 2010
- Last updated
- 10 May 2017
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Saxena P, Hall EA, Prendergast M. A Randomized Study of Incentivizing HIV Testing for Parolees in Community Aftercare. AIDS Educ Prev. 2016 Apr;28(2):117-27. doi: 10.1521/aeap.2016.28.2.117.
PubMed 27459163
Study at a glance
From the registry record, last updated by the sponsor on 10 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Using Incentives to Improve Parolee Participation and Attendance in Community Tx
- ClinicalTrials.gov ID
- NCT01090245
- Acronym / sponsor ID
- PIP / 1R01DA025627-01A1
- Conditions
- Substance Abuse, HIV Infections
- Keywords
- contingency management, substance abuse treatment, criminal justice populations, substance abuse treatment retention, HIV prevention in criminal justice settings, voucher based reinforcement therapy, Parole treatment admission for substance abusing parolees, Parole treatment retention for substance abusing parolees
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 202 participants (actual)
- Lead sponsor
- University of California, Los AngelesUniversity, hospital or other
- Study start
- Apr 2010
- Primary completion
- Jan 2014 (actual)
- Study completion
- Aug 2014 (actual)
- First posted
- 19 Mar 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment program to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.
Detailed description
A considerable body of research indicates that prison-based treatment followed by continuing treatment in the community is effective in reducing drug abuse and crime among drug-abusing offenders. However, the impact of providing treatment is less than optimal because offenders often fail to follow through on treatment referrals, leave treatment early, or have poor engagement in treatment activities. In particular, participation in prison-based treatment alone is seldom effective in reducing drug use or recidivism unless it is followed by participation in community treatment. For correctional systems that provide a continuum of care model from prison to community, low rates of admission and retention result in poor outcomes and poor resource utilization. One way to address this problem is to provide incentives to parolees for community treatment participation. Although research supports the effectiveness of behavioral reinforcement, mainly in the form of contingency management (CM), for general substance abuse populations, CM has not yet been tested or adapted for use in community-based programs for offender populations, particularly to encourage treatment attendance.
In addition, recent research has documented elevated rates of HIV infection among incarcerated populations compared to the general population, with prevalence of HIV among inmates in US prisons being estimated to be 6 to 10 times higher than in the general population. Upon release from prison, parolees often immediately resume high-risk behaviors that they engaged in prior to incarceration. Because of the high level of exposure to HIV infection that accompanies drug use, particularly by injection, drug treatment programs for high-risk offenders can serve as a valuable setting for preventing the spread of HIV, both through HIV prevention/education activities and through access to HIV testing and counseling.
Under funding from the National Institute on Drug Abuse, the UCLA Integrated Substance Abuse Programs (ISAP), in collaboration with Walden House and the California Department of Corrections and Rehabilitation, is conducting a five-year study that will involve a randomized test of the use of incentives with parolees in a community-based residential substance abuse treatment to increase treatment admission and treatment retention, and thereby increase the likelihood of improved outcomes. Study participants will be recruited from clients in a prison-based treatment program who have a referral to the Walden House community program. The Admission Phase of the study assesses the effect of an incentive (voucher) on enrolling in the Walden House program. The Attendance Phase assesses the effect of incentives on treatment attendance and on post-treatment drug use, crime, and psychosocial behaviors, including HIV risk behaviors. In addition, an incentive protocol will test whether an incentive will encourage participation in HIV testing and counseling. The intervention will last for six months.
Hypothesis 1. The use of incentives will significantly increase subject enrollment in community treatment.
Hypothesis 2. The use of incentives will significantly increase subject retention in community treatment.
Huypothesis 3. The use of incentives will significantly increase subject participation in HIV testing and counseling.
Study participants will be interviewed at baseline and at 12 months following the intervention. Treatment and criminal justice data will be obtained. Data on acceptability, satisfaction, and sustainability will be collected from focus groups with staff and clients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Attendance Information Group | Active comparator | Behavioral: InformationParticipants in the Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. In addition, they will receive the standard treatment offered by the Walden House Los Angeles program. |
| Attendance Incentive Group | Experimental | Behavioral: Contingency management: voucher/monetary incentives for treatment attendanceParticipants in the Attendance Incentive Group could receive up to $841.50 in incentives for their treatment attendance and the standard treatment offered by the Walden House Los Angeles program. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- At least 18 years of age
- English speaking
- Within one month of parole
- Able to provide informed consent to participate in the study
- Received a referral to the Walden House Los Angeles Transitional Treatment Center
Key exclusion criteria (1 listed)
- Potential subjects will be excluded from participating if they have serious cognitive problems that preclude their ability to provide informed consent or understanding of the questionnaire items, if they are a sexually violent predator or a child molester or if they have severe mental health problems.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Contingency management: voucher/monetary incentives for treatment attendanceContingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance. | Behavioural | Attendance Incentive Group |
| InformationAttendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing. | Behavioural | Attendance Information Group |
Primary outcome
Community treatment admission
Time frame: Within 7 days of release to parole
Community treatment retention
Time frame: 6 months
Participation in HIV testing and counseling
Time frame: 2 months
3 secondary outcomes
Substance abuse
Time frame: 18 months after release from prison
Arrest and reincarceration
Time frame: 18 months after release from prison
psychosocial: employment, education, family relationships, psychological functioning, and HIV risk
Time frame: 18 months after release from prison
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 May 2017.
- Results publication: PubMed 27459163Saxena P, Hall EA, Prendergast M. A Randomized Study of Incentivizing HIV Testing for Parolees in Community Aftercare. AIDS Educ Prev. 2016 Apr;28(2):117-27. doi: 10.1521/aeap.2016.28.2.117.
Related trials for Substance Abuse
RecruitingPhase 3
Nabilone for Agitation Blinded Intervention Trial
Alzheimer Disease, Agitation
Recruiting
The Trans-Led Care Study
Substance Abuse, Substance Addiction
Active, not recruitingPhase 1
Psilocybin-assisted Treatment for Cannabis Use Disorder
Cannabis Use Disorder
Not yet recruitingEarly Phase 1
Lung Health and Breath Biomarkers: Acute Effects of Inhaled Cannabis
Cannabis Use, Tobacco
Recruiting
Young Adult Tobacco/Nicotine and Cannabis Co-use
Tobacco Use Disorder, Nicotine Dependence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Michael L Prendergast, Ph.D. principal investigator
University of California, Los Angeles
Elizabeth A Hall, Ph.D. study director
University of California, Los Angeles
Questions about this trial
What is this clinical trial studying?
A study testing Contingency management: voucher/monetary incentives for treatment attendance and Information in people with Substance Abuse and HIV Infections, run by University of California, Los Angeles.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 May 2017. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Community treatment admission (time frame: Within 7 days of release to parole). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01090245, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 May 2017.